Cohance lifesciences Limited has submitted its quarterly regulatory certificate to stock exchanges, fulfilling mandatory compliance requirements under SEBI depositories regulations. The pharmaceutical company filed the certificate on April 02, 2026, covering the quarter ended March 31, 2026.

Regulatory Filing Details

The company submitted the certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 to both major stock exchanges where its shares are listed. Himanshu Agarwal, Whole-time Director and Chief Financial Officer, signed the submission on behalf of the company.

Stock Exchange Submissions

The regulatory certificate was filed with both BSE Limited and National Stock Exchange of India Limited, confirming the company's adherence to listing compliance requirements.

Registrar Confirmation

KFin Technologies Limited, acting as the company's Registrar and Share Transfer Agent, issued confirmation certificates to both depositories. C Shobha Anand, Vice President at KFin Technologies, certified that all details of securities dematerialized and rematerialized during the quarter have been furnished to stock exchanges as required.

The filing represents routine quarterly compliance by Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, ensuring transparency in securities transactions and maintaining regulatory adherence for its listed shares.

Cohance lifesciences Limited has announced a key leadership appointment, naming Mr. Sisir K. Mishra as Company Secretary, Compliance Officer and Key Managerial Personnel. The appointment was approved by the Board of Directors at their meeting held on March 30, 2026, following recommendations from the Nomination and Remuneration Committee.

Appointment Details

The new appointment will be effective from April 9, 2026. Mr. Mishra holds membership number F8555 with the Institute of Company Secretaries of India and will assume multiple critical roles within the organization's governance structure.

Professional Background

Mr. Sisir K. Mishra brings substantial expertise to his new role at Cohance Lifesciences Limited. He is a Fellow Member of the Institute of Company Secretaries of India and holds an LL.M. from Osmania University. His professional experience spans over two decades in corporate secretarial, legal, governance, CSR and ESG functions across diversified sectors.

Key Experience Areas

Mr. Mishra's expertise encompasses several critical business functions:

• Board governance and regulatory interface management
• Mergers and acquisitions oversight
• Fundraising and IPO readiness preparation
• Compliance management systems implementation
• Corporate social responsibility and ESG initiatives

Previous Professional Experience

Prior to joining Cohance Lifesciences Limited, Mr. Mishra served as Company Secretary with several prominent organizations. His previous roles include positions at NCC Limited, Paradeep Phosphates Limited, Deccan Cements Limited and KSK Group, among others. This diverse experience across infrastructure, manufacturing, IT and power sectors positions him well for his new responsibilities.

Regulatory Compliance

The appointment has been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled all disclosure requirements as mandated by SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The appointment reflects the company's commitment to maintaining robust governance standards and regulatory compliance.